EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1–2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07)

Sabine R de Wild iD, Lori M van Roozendaal, Johannes H W de Wilt iD, Thijs van Dalen, Jos A van der Hage, Frederieke H van Duijnhoven, Janine M Simons, Robert-Jan Schipper, Linda de Munck iD, Sander M J van Kuijk iD, Liesbeth J Boersma, Sabine C Linn und 8 weitere

British Journal of Surgery · 2024

DOI: 10.1093/bjs/znae077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Surgery, 2024. Verfasst von Sabine R de Wild und 19 weiteren Autor:innen. Beteiligte Einrichtung: Maastricht University Medical Centre+, Department of Surgery, GROW School for Oncology and Reproduction, Maastricht, The Netherlands. Hauptthemen laut MEDLINE: Breast Neoplasms, Sentinel Lymph Node. Die Arbeit wurde bisher 17-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Dutch Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trials have demonstrated the safety of omitting completion axillary lymph node dissection in patients with cT1–2 N0 breast cancer operated with breast-conserving surgery who have limited metastatic burden in the sentinel lymph node. The aim of this registry study was to provide insight into the oncological safety of omitting completion axillary treatment in patients operated with mastectomy who have limited-volume sentinel lymph node metastasis.

Methods

Women diagnosed in 2013–2014 with unilateral cT1–2 N0 breast cancer treated with mastectomy, with one to three sentinel lymph node metastases (pN1mi–pN1a), were identified from the Netherlands Cancer Registry, and classified by axillary treatment: no completion axillary treatment, completion axillary lymph node dissection, regional radiotherapy, or completion axillary lymph node dissection followed by regional radiotherapy. The primary endpoint was 5-year regional recurrence rate. Secondary endpoints included recurrence-free interval and overall survival, among others.

Results

In total, 1090 patients were included (no completion axillary treatment, 219 (20.1%); completion axillary lymph node dissection, 437 (40.1%); regional radiotherapy, 327 (30.0%); completion axillary lymph node dissection and regional radiotherapy, 107 (9.8%)). Patients in the group without completion axillary treatment had more favourable tumour characteristics and were older. The overall 5-year regional recurrence rate was 1.3%, and did not differ significantly between the groups. The recurrence-free interval was also comparable among groups. The group of patients who did not undergo completion axillary treatment had statistically significantly worse 5-year overall survival, owing to a higher percentage of non-cancer deaths.

Conclusion

In this registry study of patients with cT1–2 N0 breast cancer treated with mastectomy, with low-volume sentinel lymph node metastasis, the 5-year regional recurrence rate was low and comparable between patients with and without completion axillary treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsSentinel Lymph NodeHumansFemaleSentinel Lymph Node BiopsyMastectomyLymphatic MetastasisLymph Node ExcisionMastectomy, SegmentalAxillaRegistriesLymph Nodes

Autor:innen und Institutionen

  • Maastricht University Medical Centre+, Department of Surgery, GROW School for Oncology and Reproduction, Maastricht, The Netherlands.
  • Department of Surgery, Zuyderland Medical Centre, Heerlen, the Netherlands.
  • Department of Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Department of Surgery, Erasmus Medical Centre, Rotterdam, the Netherlands.
  • Department of Surgery, Leiden University Medical Centre, Leiden, the Netherlands.
  • Department of Surgery, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.

ORCID-Profile: Sabine R de Wild, Johannes H W de Wilt, Linda de Munck, Sander M J van Kuijk

Förderung

  • Dutch Cancer Society

Zitieren

APA

de Wild, S. R., van Roozendaal, L. M., de Wilt, J. H. W., van Dalen, T., van der Hage, J. A., van Duijnhoven, F. H., Simons, J. M., Schipper, R. J., de Munck, L., van Kuijk, S. M. J., Boersma, L. J., Linn, S. C., Lobbes, M. B. I., Poortmans, P. M. P., Tjan-Heijnen, V. C. G., van de Vijver, K. K. B. T., de Vries, J., Westenberg, A. H., Strobbe, L. J. A., & Smidt, M. L. (2024). De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1–2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07). British Journal of Surgery. https://doi.org/10.1093/bjs/znae077

Vancouver

de Wild SR, van Roozendaal LM, de Wilt JHW, van Dalen T, van der Hage JA, van Duijnhoven FH, et al. De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1–2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07). British Journal of Surgery. 2024. doi:10.1093/bjs/znae077

BibTeX
@article{deWild2024,
  author = {de Wild, Sabine R and van Roozendaal, Lori M and de Wilt, Johannes H W and van Dalen, Thijs and van der Hage, Jos A and van Duijnhoven, Frederieke H and Simons, Janine M and Schipper, Robert-Jan and de Munck, Linda and van Kuijk, Sander M J and Boersma, Liesbeth J and Linn, Sabine C and Lobbes, Marc B I and Poortmans, Philip M P and Tjan-Heijnen, Vivianne C G and van de Vijver, Koen K B T and de Vries, Jolanda and Westenberg, A Helen and Strobbe, Luc J A and Smidt, Marjolein L},
  title = {De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1–2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07)},
  journal = {British Journal of Surgery},
  year = {2024},
  doi = {10.1093/bjs/znae077}
}
Kostenlos starten →